Author

Mamadou Barry

Harvard University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:flow cytometry· 1 Assay:imaging· 1 Assay:proteomics· 1

Frequent Co-Authors

Amy K. BarczakiD· 2 shared Gregory E. EdelsteiniD· 2 shared Jacob E. LemieuxiD· 2 shared Jeffrey A. SparksiD· 2 shared Jonathan Z. LiiD· 2 shared Julie BoucauiD· 2 shared Karry Su· 2 shared Manish Chandra ChoudharyiD· 2 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Amy K. BarczakORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Post-infection immune response in adults with COVID-19 with and without nirmatrelvir-ritonavir treatment and virologic rebound

Dibya Ghimire, Chloe M. Hasund, John Bianchi Colangeli, May Yee Liew, Emory Abar, Mamadou Barry, Andrew Alexandrescu, Benjamin L. Kotzen, Zahra Reynolds, Eliza Passell, Chase B. Mandell, Zoie Smith-Sparks, Karry Su, Julie Boucau, Owen T. Glover, , Jacob E. Lemieux

This study examines immune responses in adults with COVID-19 who received or did not receive nirmatrelvir-ritonavir, finding no differences in immune markers between those with and without virologic rebound.

bioRxiv · Jun 23, 2026 · PreprintImmunology

Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance

Tin Phan, Ruy Miguel Ribeiro, Gregory E. Edelstein, Julie Boucau, Rockib Uddin, Caitlin Marino, May Y. Liew, Mamadou Barry, Manish Chandra Choudhary, Dessie Tien, Karry Su, Zahra Reynolds, Yijia Li, Shruti Sagar, Tammy D. Vyas, , Alan S. Perelson

The paper models viral rebound after nirmatrelvir-ritonavir treatment, finding that target cell preservation and incomplete viral clearance drive rebound, with extended treatment reducing this risk.

Journal of Virology · Feb 4, 2025Peer-reviewedImmunology